{
  "@context": "https://frontierpicks.com/schemas/dossier.v1.json",
  "ticker": "BRKR",
  "name": "Bruker Corporation",
  "url": "https://frontierpicks.com/dossiers/BRKR/",
  "json_url": "https://frontierpicks.com/dossiers/BRKR.json",
  "status": "DORMANT",
  "current_conviction": "LOW",
  "graded_conviction": "LOW",
  "archetype": {
    "code": "a4",
    "n": 4
  },
  "current_thesis": "Post-ASMS instrument re-rate broke back toward the $64.54 high and added a second leg: semiconductor-metrology strength (orders +20% YoY) pulled Leerink to $70 and top targets to $65–70. But at ~$62 the name sits ~13% over its 50-DMA and above the $56.79 consensus mean, into a binary Aug 4 Q2 print for a story that isn't earnings-driven — strong tape, rich fresh entry.",
  "invalidation_trigger": "A weekly close below $54 loses the June higher-low shelf and the rising 50-day line, reopening mean-reversion toward the pre-ASMS low-$40s base; secondarily, an Aug 4 Q2 print with organic revenue still negative, or a priced common-equity takedown off the June universal shelf, breaks the re-rate.",
  "catalyst_date": null,
  "outcome": "INVALIDATED",
  "outcome_date": "2026-08-04",
  "invalidation_fired": true,
  "themes": [
    "medtech-diagnostics",
    "ai-chips-memory",
    "physical-ai-robotics"
  ],
  "tags": [],
  "sources": [],
  "notes": [
    "Universal shelf S-3ASR live since 2026-06-12; $600M 6.375% mandatory convertible preferred ranks ahead of the common — structural dilution is already scheduled.",
    "Guidance is non-GAAP only. Q2 2026 GAAP diluted EPS was $(0.41) versus $0.49 non-GAAP, on a $134.9M non-cash goodwill impairment.",
    "German manufacturing base makes EUR/USD an idiosyncratic swing factor in reported-vs-organic revenue versus US-heavy tools peers.",
    "MIMETAS (2026-08-10) and Atinary (2026-08-11) were announced with terms undisclosed; consideration is not sizeable until the Q3 10-Q.",
    "Common dividend $0.05/share declared 2026-08-14, record 2026-09-21, payable 2026-10-07; preferred dividend $3.9844/share pays 2026-09-01.",
    "No Q3 2026 earnings date confirmed as of 2026-08-16; the historical cadence points to early November."
  ],
  "body_markdown": "## Current Thesis\nThe 2026-08-04 Q2 print resolved the binary and split the story in two. Profitability delivered: non-GAAP EPS $0.49, up 53% YoY, against $0.39 consensus, on non-GAAP gross margin of 52.1% (+350bps) and non-GAAP operating margin of 14.1% (+510bps). Organic revenue turned positive at +2.8% YoY (+3.4% excluding tariff refunds) after a negative Q1. The top line still missed — $838.5M reported versus $853.5M consensus — and management cut the FY26 revenue guide to $3.54–3.57B from $3.57–3.60B while affirming non-GAAP EPS of $2.10–$2.15. A $134.9M non-cash goodwill impairment put GAAP diluted EPS at $(0.41). The tape traded the revenue line and the guide: GuruFocus's Q2 call summary put the 2026-08-04 close at $52.83 (-17.9%), while StockStory logged an 11.9% intraday drop the same session; by the 2026-08-14 close of $57.70 the shares had recovered part of that, sitting 10.3% under the $64.34 52-week high with RSI(14) at 46.8. What an investor is buying now is a margin-and-bookings recovery (BSI bookings +10% organic, book-to-bill above 1.0x) inside a catalyst vacuum — no dated company event until the Q3 print, expected early November.\n\n## Bull Case\n- **Organic growth turned.** Q2 organic revenue +2.8% YoY (+3.4% ex tariff refunds) versus first-half organic of -0.8% and scientific-instrument organic of -1.4% (2026-08-04 release). The FY26 +1–2% organic guide now needs continuation, not a reversal.\n- **Margins are doing the work.** Non-GAAP operating margin 14.1%, +510bps YoY; gross margin 52.1%, +350bps; non-GAAP EPS $0.49 versus $0.32 in Q2 2025. That is what let the EPS guide hold while the revenue guide came down.\n- **Orders lead the P&L.** BSI revenue $767.3M (+4.7% reported, +2.3% organic) with bookings +10% organic YoY and book-to-bill above 1.0x; the CEO cited order strength in semiconductor tools, energy research and biopharma (2026-08-04).\n- **BEST is compounding.** The energy/superconductor segment printed $74.2M, +11.9% reported and +8.9% organic — a second revenue line levered to grid and magnet demand rather than academic budgets.\n- **The platform kept widening after the print.** Majority investment in organ-on-a-chip developer MIMETAS announced 2026-08-10; expanded strategic collaboration plus minority investment in self-driving-labs firm Atinary announced 2026-08-11. Terms undisclosed on both.\n- **Spot sits under the analyst median.** Consensus aggregators retrieved 2026-08-16 show a median 12-month target near $60 across 13 analysts, range $40–$70, split 8 buy / 4 hold / 1 sell.\n\n## Bear Case\n- **The revenue guide came down.** FY26 sales cut $30M at both ends to $3.54–3.57B on 2026-08-04 against a $3.589B consensus; the affirmed $2.10–$2.15 EPS range is being carried by margin expansion while the volume line shrinks.\n- **A $134.9M goodwill impairment.** Non-cash, but it is a write-down of previously acquired value at a company that announced two more investments within six days of the print, both with undisclosed terms.\n- **Liquidity is thinner.** Cash of $184.9M at 2026-06-30, down from $298.8M at year-end 2025, against long-term debt of $1,814.7M and current debt of $10.1M.\n- **The dilution channel is open.** The 2026-06-12 universal S-3ASR (common, preferred, debt, warrants, units) remains live, and $600M of 6.375% mandatory convertible preferred ranks ahead of the common — its $3.9844/share quarterly dividend was declared 2026-07-30 and pays 2026-09-01.\n- **A desk cut into the recovery.** Citigroup maintained Neutral and lowered its target to $53 on 2026-08-05, below the 2026-08-14 close of $57.70.\n- **US academic demand has not inflected.** Management said NIH outlays had not yet translated into meaningful Q2 orders; Europe and China carried the academic line.\n\n## Setup & Price Structure\nThe narrative is **maturing**. Dated by three things — the 2026-08-04 print, which validated the margin and bookings leg while removing the beat-and-raise leg; the guide cut that took the story off the acceleration path; and the partial recovery into 2026-08-14, which shows the bid survived without the narrative expanding. This is not saturated (RSI(14) 46.8, 10.3% below the high, no mainstream retail coverage cluster) and not dead (organic growth positive, bookings +10% organic, the recovery off the reaction close is real).\n\nStructure the market is trading against: the $64.34 52-week high on the adjusted series; the $52.83 reaction close attributed to the 2026-08-04 session; the ~$55 shelf built through June, which the print cut straight through; and the 2026-08-14 close of $57.70 inside that post-event range.\n\nCrowding and positioning observables, stated as observables: the late-July extension above the 50-day line has been worked off — RSI(14) is 46.8 and the three-month return is still +34.7%, so the move is intact but no longer stretched. There is no earnings date inside the next 30 days. The live universal shelf plus two undisclosed-consideration deals in August is the issuance-into-strength item to monitor; any 424B prospectus supplement would be the observable. No insider transactions appear in the current filing set for this window.\n\n## Catalyst Calendar (next 30 days)\n\n- **2026-09-01** — Payment of the $3.9844/share quarterly dividend on the 6.375% Mandatory Convertible Preferred Series A (declared 2026-07-30, record 2026-08-15). Cash outflow marker and a standing reminder of the conversion overhang above the common.\n- **2026-09-21** — Record date for the $0.05/share common dividend declared 2026-08-14, payable 2026-10-07. Small, but it confirms the board did not touch the payout after the guide cut.\n- **No dated company catalyst inside the 30-day window.** The next event that resolves anything is the Q3 2026 print, expected **~2026-11-04 (est.)** — no date confirmed as of 2026-08-16.\n\n## Elapsed catalysts\n\n- **Undated, filing-driven** — any 424B prospectus supplement off the 2026-06-12 shelf; the Q3 10-Q, which is where MIMETAS and Atinary consideration would first appear. *(passed 75d ago)*\n\n## What Would Change Our Mind\nThe structure that matters is the floor the print itself created. The August selloff cut through the June shelf near $55 and set a reaction close around $52.83; the recovery to $57.70 by 2026-08-14 is what a buyer of the margin story is defending. A weekly close below $52 gives that back entirely and reframes the guide cut as a de-rate rather than a one-quarter reset. Secondary conditions that would break the frame independent of price: a priced common-equity takedown off the June universal shelf, which would use the recovery as the funding window; a Q3 print (est. ~2026-11-04) with organic growth back below zero or a second FY26 revenue trim; or another goodwill charge, which would put the acquisition cadence itself in question. On the other side, the read strengthens if BSI bookings hold double-digit organic growth into Q3 and management quantifies semiconductor-metrology orders again — that number was the second narrative leg in the first half and it went uncited in the Q2 headline figures.\n\n## Correlation Notes\n- **Life-science tools complex** — TMO, DHR, A, WAT, RVTY. Bruker's Q2 message (soft US academic, better Europe/China, margin expansion carrying EPS) is the sector's shared script; a peer guide cut on academic or pharma capex tends to reprice the group together.\n- **NIH/US federal research funding** — management explicitly flagged NIH outlays not yet converting to orders. Appropriations headlines move the academic order book before they move revenue.\n- **AI capex / advanced packaging** — the semiconductor-metrology order line (flagged above +20% YoY in Q4 2025 and Q1 2026) ties a slice of BSI to the same spend cycle as front-end and packaging metrology names. That linkage is only as durable as the next quantified order disclosure.\n- **EUR/USD** — a German manufacturing base makes the reported-versus-organic gap unusually FX-sensitive relative to US-heavy peers; the FY26 guide was framed against a meaningful FX headwind.\n- **Rates/credit** — $1,814.7M long-term debt plus a live universal shelf make the name more sensitive to issuance windows than instrument peers carrying net cash.",
  "first_seen": "2026-06-05",
  "last_analyzed": "2026-08-16T14:35:17+00:00",
  "last_synthesized": "2026-08-16",
  "last_update_source": "watchlist_research",
  "license": "Content © FrontierPicks. Cite the canonical URL."
}